Deutsche Märkte schließen in 1 Stunde 15 Minute

Amneal Pharmaceuticals, Inc. (2DT.F)

Frankfurt - Frankfurt Verzögerter Preis. Währung in EUR
Zur Watchlist hinzufügen
4,6600-0,0800 (-1,69%)
Ab 9:16AM MESZ. Markt geöffnet.

Amneal Pharmaceuticals, Inc.

400 Crossing Boulevard
3rd Floor
Bridgewater, NJ 08807
United States
908 947 3120
http://www.amneal.com

Sektor(en)Healthcare
BrancheDrug Manufacturers—Specialty & Generic
Vollzeitmitarbeiter6.000

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Chirag K. PatelCo-Founder, Co-CEO, Pres & Director22,04kN/A1967
Mr. Chintu Patel R.Ph., R.PhCo-Founder, Co-CEO & Director29,85kN/A1972
Mr. Anastasios G. KonidarisExec. VP & CFO856,85kN/A1967
Ms. Nikita ShahExec. VP and Chief HR Officer & Strategic Planning Officer720,52kN/A1978
Mr. Joseph Todisco MBAExec. VP & Chief Commercial Officer of Specialty790,12kN/A1976
Mr. Andrew S. BoyerExec. VP & Chief Commercial Officer of Generics1,15MN/A1966
Mr. Stephen J. ManzanoSr. VP, Gen. Counsel & Corp. Sec.N/AN/A1965
Mr. Sanjiv PatelSr. VP of OperationsN/AN/AN/A
Dr. Nikunj PatelHead of Ops & Exec. VP of Amneal Pharmaceuticals (India) Pvt LtdN/AN/AN/A
Mr. Sanjay Kumar JainPres of India OperationsN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2020 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed, owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinson's disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.

Corporate Governance

Amneal Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. April 2021, lautet 6. Die grundlegenden Scores sind Audit: 8, Vorstand: 9, Shareholderrechte: 4, Kompensation: 4.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.